NEUROPACE, INC. (NPCE) Operating Margin
- Operating margin · 12 months: Value -11.34%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -11.34% | Operating income / revenue. Period ending 2026-06-30. $-12.14M ÷ $106.99M × 100 ≈ -11.34% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -12.14M USD | Operating Income (Loss) |
| Revenue | 106.99M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 24.20M USD | Cost of Goods and Services Sold |
| Research and development | 27.69M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-12.14M | $106.99M | $24.20M | $27.69M | (m) | -11.34% |
| 2026-03-31 | $-16.76M | $99.53M | $21.60M | $27.64M | (m) | -16.84% |
| 2025-12-31 | $-16.34M | $99.99M | $22.77M | $27.89M | (m) | -16.34% |
| 2025-09-30 | $-18.22M | $94.86M | $22.03M | $26.91M | (m) | -19.21% |
| 2025-06-30 | $-19.87M | $88.57M | $21.49M | $26.09M | (m) | -22.43% |
| 2025-03-31 | $-19.27M | $84.31M | $21.22M | $25.31M | $57.05M | -22.86% |
| 2024-12-31 | $-21.67M | $79.91M | $20.82M | $23.65M | $57.10M | -27.12% |
| 2024-09-30 | $-23.07M | $76.45M | $20.01M | $22.98M | $56.53M | -30.17% |
| 2024-06-30 | $-24.78M | $71.82M | $18.56M | $22.02M | $56.01M | -34.50% |
| 2024-03-31 | $-26.40M | $69.07M | $17.98M | $21.30M | $56.19M | -38.22% |
| 2023-12-31 | $-27.17M | $65.42M | $17.30M | $20.78M | $54.52M | -41.54% |
| 2023-09-30 | $-31.98M | $60.20M | $16.82M | $20.49M | $54.87M | -53.13% |
| 2023-06-30 | $-36.23M | $54.93M | $15.82M | $21.31M | $54.04M | -65.96% |
| 2023-03-31 | $-39.35M | $48.62M | $14.01M | $21.63M | $52.33M | -80.94% |
| 2022-12-31 | $-40.79M | $45.52M | $13.03M | $21.95M | $51.34M | -89.62% |
| 2022-09-30 | $-39.95M | $43.73M | $11.96M | $22.20M | $49.51M | -91.36% |
| 2022-06-30 | $-35.99M | $42.91M | $11.60M | $20.92M | $46.38M | -83.88% |
| 2022-03-31 | $-29.63M | $45.34M | $12.14M | $19.69M | $43.14M | -65.34% |
| 2021-12-31 | $-23.74M | $45.18M | $11.75M | $18.21M | $38.96M | -52.54% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-13.05M | $41.14M | $10.87M | $15.70M | $27.63M | -31.72% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |
| CERUS CORP (CERS) | United States | $0.525B | -86.40 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| DELCATH SYSTEMS, INC. (DCTH) | United States | $0.558B | 820.33 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| SS Innovations International, Inc. (SSII) | $0.589B | -64.06 | |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |